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Purpose. To compare laser peripheral iridotomy (LPI) with trabeculectomy as an initial treatment for primary angle-closure
glaucoma (PACG) with peripheral anterior synechiae (PAS)≥ 6 clock hours. Methods. Patients were drawn from two
randomized controlled trials. 38 eyes of 38 patients (PAS≥ 6 clock hours) were treated with LPI (group 1) while 111 eyes of 111
PACG patients (PAS≥ 6 clock hours) underwent primary trabeculectomy (group 2). All patients underwent a comprehensive
ophthalmic examination at baseline and at postoperative visits and were followed up for a minimum of one year. Results. Group
2 had higher baseline IOP (45.7± 14.8mmHg versus 34.3± 14.3mmHg) than group 1 and more clock hours of PAS (10.4± 1.9
versus 9.0± 2.2). IOPs at all postoperative visits were signiﬁcantly lower in group 2 than in group 1 (p = 0 000). Five eyes in
group 1 required trabeculectomy. 17 of the 38 eyes in group 1 (44.7%) required IOP-lowering medications as compared to seven
of the 111 eyes in group 2 (6.3%). Cataract progression was documented in 2 eyes (5.3%) in group 1 and 16 eyes (14.4%) in
group 2. Conclusions. Primary trabeculectomy for PACG (PAS≥ 6 clock hours) is more eﬀective than LPI in lowering IOP.
1. Introduction
Primary angle-closure glaucoma (PACG) is the major type of
primary glaucoma in China [1–4]. The management of
PACG in China is diﬀerent from the recommendations of
the American Academy of Ophthalmology Preferred Practice
Patterns (PPP) and other published guidelines [5–7]. For
primary angle closure (PAC) and PACG, the PPP recom-
mends laser peripheral iridotomy (LPI) to eliminate pupil-
lary block followed by a treatment strategy “similar to that
for POAG” [8]. Accordingly, LPI is used as the ﬁrst-line
treatment for all patients with PAC or PACG, medication is
added as needed, and surgery is considered when the intraoc-
ular pressure (IOP) cannot be controlled with maximum
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tolerated medications. In China, however, trabeculectomy is
considered a primary option for PACG and is generally
undertaken if peripheral anterior synechiae (PAS) are greater
than 6 clock hours [9, 10]. To the best of our knowledge,
there is no comparative study of LPI versus primary trabecu-
lectomy in PACG to support such an approach. Using data
from patients enrolled in two separate randomized con-
trolled trials [11, 12], we compared the IOP-lowering eﬃcacy
and safety of LPI versus trabeculectomy as an initial treat-
ment for PACG with PAS≥ 6 clock hours.
2. Methods
Patients included in this study had participated in 2 random-
ized clinical trials (RCTs) for PACG. Both trials were
conducted in accordance with the tenets of the Declaration
of Helsinki and approved by the ethics committee of the
Tongren Eye Centre, Capital Medical University. Written
informed consent was obtained from all subjects for partici-
pation in the original trials.
Patients undergoing primary trabeculectomy for PACG
had participated in a multicenter RCT (registration number:
ChiCTR-TCR-00000218) [12]. This RCT was conducted in
four clinical collaborative centers of Beijing Tongren Hospi-
tal: Handan 3rd Hospital (Hebei Province, China), Anyang
Eye Hospital (Henan Province, China), Fushun Eye Hospital
(Liaoning Province, China), and the Chenzhou Eye and
Optometry Center (Hunan Province, China). PACG was
deﬁned as primary angle closure with glaucomatous optic
neuropathy and corresponding visual ﬁeld defects, and
patients were recruited from the four centers between April
2006 and November 2007. The primary purpose of the trial
was to report the eﬃcacy and complications of trabeculect-
omy with or without releasable sutures in PACG.
Patients who underwent LPI as an initial treatment were
part of another RCT (registration number: ChiCTR-TRC-
00000034, http://www.chictr.org.cn) conducted at the Han-
dan 3rd Hospital [11]. The purpose of this RCT was to
investigate the role of laser iridotomy (with or without
iridoplasty) in patients with synechial PAC or PACG. The
deﬁnition of PACG was the same as that used in the trial
mentioned above; consecutive cases of PAC and PACG
presenting to the hospital between October 1, 2005, and
October 31, 2006, were recruited for this trial.
2.1. Patient Selection. The inclusion criteria for the current
study were as follows:
(1) PACG: deﬁned as primary angle closure with glauco-
matous optic neuropathy and visual ﬁeld defects [13]
(2) Age 40 years or more
(3) PAS≥ 6 clock hours
(4) Minimum follow-up of one year.
Patients with acute angle-closure glaucoma were
excluded.
As part of the original clinical trial, all patients had under-
gone a comprehensive ophthalmic examination including
refraction, Goldmann applanation tonometry, static and
dynamic gonioscopy (manipulation) using a one-mirror
Goldmann gonioscope [14, 15], slit-lamp examination, fun-
dus examination, and automated perimetry (Humphrey Field
Analyzer 750i, Carl ZeissMeditec; Sita Fast strategy; and 24–2
threshold test). These examinations were performed at base-
line and at postoperative visits scheduled at month 1, month
3, month 6, month 12, and month 18. Postoperative visits
were scheduled on day 1, day 3, week 1, week 2, month 1,
month 3, month 6, month 12, and month 18 following the
LPI or trabeculectomy.
2.2. Laser Peripheral Iridotomy. All laser procedures were
performed by one of two senior glaucoma specialists. 2%
pilocarpine was applied, and iridotomy was performed under
topical anesthesia using a Nd:YAG laser (YL-1600; NIDEK
Co. Ltd., Japan) using an Abraham contact lens (Ocular
Instruments Inc., Bellevue, USA). A treatment site was
selected in the superior nasal iris or in a crypt where present.
The treatment was initiated with a single 4mJ pulse, the
power was adjusted, and the treatment was continued to
obtain a 0.2mm opening; patency was determined by direct
visualization of the posterior chamber.
In accordance with local practice, IOP-lowering medica-
tion was initiated if the IOP was greater than 21mmHg
following laser and conﬁrmed by a repeat reading on the
same day [11].
2.3. Trabeculectomy. Surgery was performed under topical or
peribulbar anesthesia using a standard surgical technique.
The eye was prepared using a standard aseptic technique
and draped to isolate the lashes. A lid speculum was inserted
and a 7/0 superior rectus muscle traction suture was placed.
A limbus-based conjunctival ﬂap was created using a
10mm incision through the conjunctiva and Tenon’s cap-
sule approximately 8–10mm from the limbus. The ﬂap
was dissected forwards and hemostasis achieved with
monopolar diathermy.
A half-thickness 4× 3mm2 rectangular scleral ﬂap was
fashioned, and cellulose sponges soaked in MMC (0.3mg/
ml) were applied under the scleral ﬂap, conjunctiva, and
Tenon’s capsule for a duration determined by the surgeon
based on an assessment of risk factors. Irrigation with bal-
anced salt solution was performed to wash out residual
MMC solution. A paracentesis was created, a 2× 1.5mm
trabeculectomy block excised, and an iridectomy performed.
The scleral ﬂap was sutured with 10-0 monoﬁlament, BSS
was injected into the anterior chamber to assess ﬂow, and
the conjunctiva was closed with a single running 8/0 vicryl
suture [12].
Visual acuity was recorded with a decimal chart and
converted to the logarithm of minimum angle of resolution
(LogMAR) format. Finger counting, hand movement, and
light perception were recorded as 1.5, 2.0, and 2.5 on the
LogMAR scale.
At each postoperative visit, a trained technician
measured the IOP twice using an applanation tonometer
and recorded the average. If the diﬀerence between the two
measurements was more than 2mmHg, a third measurement
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was performed, and the average of the two closer results was
recorded. All IOP measurements were performed between
8 am and 12 am.
At each site, trained observers used standard LOCS III
photographs to assess the lens. Cataract progression was
deﬁned as an increase of 2 or more units greater than baseline
in any LOCS III category (nuclear, cortical, or posterior
capsular opacity). Progression was analyzed in all eyes with
a minimum follow-up of 12 months; for those whose longer
follow-up was available, it was determined at the 18-month
visit. The shallow anterior chamber (AC) was categorized
as grade I = peripheral iris-cornea touch; grade II =midiris-
cornea touch; and grade III = central cornea-lens touch
[16]. Hypotony was deﬁned as IOP≤ 5mmHg [17].
At each visit, other complications and interventions, if
undertaken, were recorded.
2.4. Statistical Analysis. One eye of each patient was
randomly selected for the analysis.
Statistical analysis was carried out using SPSS 15.0 (SPSS
Inc., Chicago, USA). Independent t-test was used to com-
pare the diﬀerence between the groups, and the chi-square
test was used to compare the diﬀerence in IOP-lowing
medication and cataract progression between the groups. A
p value < 0.05 was considered signiﬁcant.
3. Results
38 eyes of the 38 patients with PACG that underwent pri-
mary iridotomy comprised group 1 while group 2 consisted
of 111 eyes of the 111 PACG patients who had undergone
trabeculectomy.
The baseline characteristics of the two groups are sum-
marized in Table 1. Patients in group 2 were slightly younger
and had higher baseline IOP and more clock hours of PAS.
Table 2 shows the postoperative IOP and visual
acuity. At each visit, the IOP was signiﬁcantly lower in
group 2 (p < 0 001).
Five eyes in group 1 required trabeculectomy: 1 eye at
6 months, 2 eyes at 12 months, and 2 eyes at 18 months.
17 of the 38 eyes (44.7%, CI: 28.9%–60.5%) in group 1
required a mean of 1.8 IOP-lowering medications while
seven of the 111 eyes (6.3%, CI: 1.8%–10.8%) in group 2
required a mean of 1.1 medications (Pearson’s chi-square
value = 30.940, p < 0 001).
19 eyes in group 2 developed a transient shallow anterior
chamber (AC), but there was no instance of lens-cornea
touch. 16 eyes (including 13 eyes with shallow AC) experi-
enced transient hypotony. Hypotony lasted one day in 14
eyes and one week in 2 eyes and all recovered spontaneously.
One eye developed hypotony maculopathy at one month
after surgery that was resolved after IOP increased 3 weeks
later. In one eye, the IOP increased to 60mmHg at 3 months
postsurgery and required cyclophotocoagulation.
Best-corrected visual acuity at 18 months was 0.5± 0.5 in
group 1 and 0.6± 0.7 in group 2. Four eyes (10.5%) in group 1
lost one line of vision, 3 eyes (7.9%) lost 2 lines, and 3 (7.9%)
lost more than 2 lines. In group 2, thirteen eyes (11.7%) lost 1
line, 9 eyes (8.1%) lost 2 lines, and 11 eyes (9.9%) lost more
than 2 lines. Six eyes in group 1 and 20 eyes in group 2 lost
≥2 lines (Pearson’s chi-square value 0.098, p = 0 755). The
absolute risk for ≥2 lost lines of vision in the trabeculectomy
group was 18% (20 of 111) compared to 16% (6 of 38) in the
LPI group. The absolute risk increased with trabeculectomy
is 2% and the number needed to harm (NNH) is 50.
Cataract progression as deﬁned was documented in 2
eyes (5.3%, CI: −1.8%–12.4%) in group 1 and 16 eyes
(14.4%, CI: 7.9%–20.9%) in group 2 (Pearson’s chi-square
value= 2.232, p = 0 135). The absolute risk increased in cata-
ract formation with trabeculectomy is 9% and translates into
a NNH of 11.
4. Discussion
The PACG treatment strategy formulated by the glaucoma
group of the Chinese Ophthalmology Society is diﬀerent
from that formulated by other published guidelines. As per
Table 1: Demographics.
Characteristics Group 1 Group 2 t value p value
Age 65.9± 7.9 62.3± 7.1 2.63 0.009
Baseline BCVA (LogMAR) 0.5± 0.5 0.5± 0.6 −0.033 0.974
Baseline IOP 34.3± 14.3 45.7± 14.8 −4.119 0.000
Baseline VCDR 0.7± 0.2 0.8± 0.1 −2.004 0.051
Baseline PAS 9.0± 2.2 10.4± 1.9 −3.892 0.000
Baseline MD −17.3± 11.9 −19.2± 10.7 0.927 0.356
LPI = laser peripheral iridotomy; BCVA= best-corrected visual acuity; LogMAR= logarithm of minimum angle of resolution; IOP = intraocular pressure;
VCDR= vertical cup/disc ratio; PAS = peripheral anterior synechiae; MD=mean deviation.
Table 2: IOP and ﬁnal BCVA after LPI and trabeculectomy.
Characteristics Group 1 Group 2 t value p value
IOP 1M 23.1± 10.0 14.0± 4.5 5.397 0.000
IOP 3M 20.2± 6.8 13.1± 4.1 6.066 0.000
IOP 6M 22.1± 6.7 13.6± 4.3 8.826 0.000
IOP 12M 19.1± 5.3 14.5± 3.5 6.145 0.000
IOP 18M 19.0± 5.3 14.9± 3.8 5.208 0.000
Final BCVA 0.5± 0.5 0.6± 0.7 −0.948 0.346
M=months; BCVA= best-corrected visual acuity; PAS = peripheral anterior
synechiae; IOP = intraocular pressure.
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Chinese guidelines, LPI is suggested for “patients with
PAS< 180° without optic disc and visual ﬁeld damage” (an
indication endorsed without data by a recent publication),
while primary trabeculectomy is recommended for PACG
with PAS≥ 180° [9, 18]. A 2005 survey of clinical practice
in PACG diagnosis and treatment found that 73% of Chinese
glaucoma specialists preferred trabeculectomy as the initial
treatment for PACG with PAS≥ 180° [10]. Evidence for
such an approach is however lacking, and to the best of
our knowledge, our study is the ﬁrst study to compare
primary LPI with primary trabeculectomy for PACG.
LPI is considered a noninvasive, simple, and safe inter-
vention in PACS, PAC, and PACG [19]. The eﬀect of a LPI
would depend on the amount of angle that is available for
ﬁltration, and this can be estimated clinically by the extent
of PAS [18, 20]. IOP control following LPI as reported in
the literature varies considerably, and the therapeutic eﬀect
seems to decrease over time [21, 22]. In a retrospective
analysis of 131 cases (251 eyes) in China, 18 eyes with PACS,
98 eyes with PAC, and 129 eyes with PACG that underwent
LPI were followed up for 9.2± 3.7 years [23]. Eyes with
PAC and PACG had PAS< 6 clock hours. At the ﬁnal follow
up, 16/18 PACS, 38/98 PAC, and 814/129 of PACG eyes were
controlled (deﬁned as IOP less than 21mmHg) without
medications. 60% of cases required additional medications
and 13% needed ﬁltering surgery.
A study from India evaluated the long-term outcome of
PACG following laser iridotomy [24]. 70 consecutive patients
with PACG whose IOP remained >21mmHg despite a
patent iridotomy had their IOP controlled by medications
or trabeculectomy and were followed up over a 6-year period.
A trabeculectomy without antimetabolites was performed if
IOP was >21mmHg on maximal tolerable medical therapy,
if there was evidence of progression of the disc/visual ﬁeld,
or if the patient was noncompliant. 46 (65.7%) eyes were
controlled medically with 26 (57%) eyes requiring two topical
medications. 24 (34.3%) eyes required trabeculectomy at
various times during follow-up. The extent of PAS was not
reported in this study, but reports suggest that the therapeu-
tic eﬀect of LPI decreases over time and many cases need
ﬁltering surgery.
The results seem consistent with the biologically plausi-
ble hypothesis that LPI is more successful in those with
relatively undamaged trabecular meshwork [18]. The litera-
ture seems to suggest that, despite the presence of a patent
LPI, eyes with established PACG and a certain (currently
undeﬁned) extent of PAS require further treatment to control
IOP and that medical therapy fails in a signiﬁcant number of
cases necessitating ﬁltering surgery [18, 25].
In the current investigation, the IOP during follow-up
was signiﬁcantly lower in the trabeculectomy group. Further-
more, a larger number of patients who underwent LPI
needed medical treatment as compared to those who under-
went trabeculectomy. In this developing country, setting
patients may not be able to aﬀord medical treatment or are
generally not adherent or persistent with it. To simulate a
real-world condition, we did not provide free IOP-lowering
medication and found that 24% of patients could not
aﬀord long-term medication. Moreover, 5 eyes (13.2%) of
patients who underwent LPI with baseline PAS≥ 6 clock
hours (group 1) had to undergo trabeculectomy during
the follow-up period.
The poor eﬀectiveness of IOP lowering following LPI for
PACG with ≥6 hours of PAS would seem important in select-
ing treatment within the well-known constraints of a devel-
oping country, including a possible one shot at treatment.
We therefore suggest that 6 clock hours of PAS can be
considered a provisional clinical threshold for LPI in PACG,
as this is likely to change with further research and will be
diﬀerent for individual cases. Our ﬁndings lend credence to
a recently published algorithm for the management of
angle-closure disease that recommended a ≥6 clock hour
threshold for PAS; that algorithm was based mainly on
biological plausibility [18]. Considering the problems of
medical treatment in developing countries, a policy of
primary trabeculectomy for PACG with ≥6 clock hours of
PAS might merit consideration. In fact, even eyes with <6
clock hours of PAS may be considered for a trabeculectomy
if the socioeconomic situation so dictates [23].
The choice of initial treatment must also consider the
issue of complications. Consistent with most other publica-
tions, we did not encounter any signiﬁcant complications in
the LPI group [11]. While complications with trabeculect-
omy are more frequent, the incidence of severe sight-
threatening complications is now less than what it was 20
years ago; we encountered mainly transient shallow chamber
and hypotony. It must be kept in mind that in our study,
trabeculectomy was undertaken by glaucoma specialists in
the context of a clinical trial and the potential for sight-
threatening complications remains. Importantly, even in
the context of a clinical trial, 18% of eyes undergoing trabecu-
lectomy lost 2 or more lines of vision. However, the number
needed to harm for ≥2 lost lines of vision is an acceptable 50.
Incision-induced astigmatism as well as progression of
cataract was the major reason for visual loss, but both would
be considered treatable. 19% of patients in undergoing trabe-
culectomy had astigmatism of >1D at 6-month visit, and
14.4% had obvious progression of lens opacity. The NNH
for progression of cataract with trabeculectomy was 11.
While successful intervention is available for cataracts, this
low NNH that could lead to an increase in the burden of
cataract is a disadvantage with trabeculectomy.
The choice for the initial intervention for PACG in China
and other developing countries must weigh up eﬀectiveness
versus complications as well as the need for additional med-
ications and further interventions. While LPI is safe and easy,
there is a more need for intensive medications and surgical
intervention. The role of cataract extraction in primary
angle-closure disease is evolving but is again more likely to
be useful for those with angles less compromised by PAS
[18, 26]. Trabeculectomy is better than LPI for lowering the
IOP, but it does have the potential for more loss of visual acu-
ity and for serious complications. Accordingly, it is probably
best to reserve primary surgical intervention for established
PACG with ≥6 clock hours as these are unlikely to do well
with laser alone. While not statistically signiﬁcant in this
study, the higher chances for progression of cataract follow-
ing trabeculectomy raise the question of combining ﬁltration
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with cataract surgery, an issue not addressed in this study. In
addition to clinical factors, any decision will also depend on
the availability of lasers and surgeons and costs.
One of the limitations in our study is the small sample
size in group 1 and the relatively short follow-up time. As
few patients progressed during this time, we could not
analyze the relationship between IOP and the visual ﬁeld
progression, but IOP would usually be considered an
acceptable surrogate. Also, our results are derived from
patients enrolled in RCTs, and the eﬀectiveness in the real
world is likely to be diﬀerent. Furthermore, as it was not
part of this study, we cannot comment on the increasingly
popular role of phacoemulsiﬁcation or its combination
with trabeculectomy in the management of PACG [18].
The low NNH for cataracts with trabeculectomy could
however be used as an argument for combining the two
surgical procedures.
Finally, while the deﬁnition of PACG used in both trials
was the same, patients for this study were drawn from two
separate trials that asked diﬀerent questions. This could
introduce signiﬁcant bias. The original LPI RCT (registration
number: ChiCTR-TRC-00000034, http://www.chictr.org.cn)
[11] that randomized patients into two diﬀerent treatment
groups (iridotomy or iridotomy plus iridoplasty) found no
signiﬁcant diﬀerence in IOP, medications, need for surgery,
or visual function between groups at the 1-year visit. This
RCT showed that in eyes with PACG, both iridotomy alone
and iridotomy combined with iridoplasty provide a signiﬁ-
cant and similar reduction in IOP. For the trabeculectomy
RCT (registration number: ChiCTR-TCR-00000218) [12],
patients were randomly allocated to permanent or releas-
able sutures. This study too did not demonstrate any sig-
niﬁcant diﬀerences between the groups. Accordingly, we
felt that analyzing patients from either arm of the two tri-
als for the current study was acceptable but acknowledge
that the possibility of unknown diﬀerences does exist and
could aﬀect interpretation. However, as the baseline IOP
was higher and PAS more extensive in the trabeculectomy
group, the conclusion in favor of trabeculectomy is likely
to stand.
In conclusion, our results support the Chinese guidelines
for management of PACG. In PACG with ≥6 clock hours of
PAS, primary trabeculectomy is more eﬀective than LPI in
lowering IOP and signiﬁcantly requires less medication but
with more progression of cataract and more loss visual
acuity. In developing countries, such as China, trabeculect-
omy can be considered a primary option for PACG with this
degree of PAS.
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